title: Primary effusion lymphoma-like lymphoma in a patient with inflammatory bowel disease.
abstract: A 77-year-old man with inflammatory bowel disease (IBD) and who was treated with anti-tumor necrosis factor (TNF), 6-mercaptopurine and corticosteroids, presented with primary effusion lymphoma-like lymphoma (PEL-like lymphoma) with massive ascites. The patient's clinical course was complicated by acute renal insufficiency and hypotension, which led to death within 2 wk. In general, patients with IBD may have an increased risk for development of lymphoma, which is frequently associated with immunosuppressive and/or anti-TNF antibody therapies. PEL is a rare subset of lymphoma localized to serous body cavities, lacks tumor mass or nodal involvement, and is associated with infection by human herpes virus 8 (HHV-8). Primary neoplastic effusion may also be present in patients with large B-cell lymphoma without evidence of human immunodeficiency virus or HHV-8 infections. This type of lymphoma is classified as PEL-like lymphoma. Both PEL and PEL-like lymphoma types have been reported in patients undergoing immunosuppressive therapy, but to the best of our knowledge, the case described herein represents the first PEL-like lymphoma occurring in a patient with IBD.
authors.affiliation: Elchanan Nussinson, Fahmi Shibli, Azmi Shahbari, Gastroenterology Institute, Emek Medical Center, Afula 18101, Israel.
authors.forename: Elchanan
authors.initials: E
authors.lastname: Nussinson
authors.affiliation: Elchanan Nussinson, Fahmi Shibli, Azmi Shahbari, Gastroenterology Institute, Emek Medical Center, Afula 18101, Israel.
authors.forename: Fahmi
authors.initials: F
authors.lastname: Shibli
authors.affiliation: Elchanan Nussinson, Fahmi Shibli, Azmi Shahbari, Gastroenterology Institute, Emek Medical Center, Afula 18101, Israel.
authors.forename: Azmi
authors.initials: A
authors.lastname: Shahbari
authors.affiliation: Elchanan Nussinson, Fahmi Shibli, Azmi Shahbari, Gastroenterology Institute, Emek Medical Center, Afula 18101, Israel.
authors.forename: Wasseem
authors.initials: W
authors.lastname: Rock
authors.affiliation: Elchanan Nussinson, Fahmi Shibli, Azmi Shahbari, Gastroenterology Institute, Emek Medical Center, Afula 18101, Israel.
authors.forename: Mazen
authors.initials: M
authors.lastname: Elias
authors.affiliation: Elchanan Nussinson, Fahmi Shibli, Azmi Shahbari, Gastroenterology Institute, Emek Medical Center, Afula 18101, Israel.
authors.forename: Irit
authors.initials: I
authors.lastname: Elmalah
mesh_terms: D000368:Aged; D001201:Ascites / Q000139:chemically induced; D001688:Biological Products / Q000009:adverse effects*; D014408:Biomarkers, Tumor / Q000032:analysis; D017809:Fatal Outcome; D006801:Humans; D016867:Immunocompromised Host; D007150:Immunohistochemistry; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D054685:Lymphoma, Primary Effusion / Q000139:chemically induced* / Q000737:chemistry / Q000000981:diagnostic imaging / Q000276:immunology; D008297:Male; D014057:Tomography, X-Ray Computed; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D001688:Biological Products; D014408:Biomarkers, Tumor; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha
keywords: Immunosuppressive therapy; Inflammatory bowel disease; Lymphoma; Primary effusion lymphoma; Primary effusion lymphoma-like lymphoma